Antibody Drug Conjugate Competitie Landscape Report (Updated) | ImmunoGen, Inc., Seagen Inc, ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, and others.

DelveInsight's, "Antibody Drug Conjugate Competitive landscape, 2025," report provides comprehensive insights about 180+ companies and 290+ drugs in Antibody Drug Conjugate Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive ADC pipeline products in this space.

Key Takeaways from the Antibody Drug Conjugate Pipeline Report
• On August 15, 2024, the FDA lifted the partial clinical hold on MediLink Therapeutics' Phase I trial for BNT326/YL202 (NCT05653752). The trial, initially put on hold in June 2024, meets FDA requirements with updated data analysis, an amended protocol, and new patient consent forms. BNT326/YL202, an HER3-targeting antibody-drug conjugate developed with BioNTech, will resume recruitment, focusing on doses up to 3 mg/kg, where safety and clinical activity were promising.
• DelveInsight's Antibody Drug Conjugate pipeline report depicts a robust space with 180+ active players working to develop 290+ pipeline therapies for Antibody Drug Conjugate treatment.
• The leading companies working in the Antibody Drug Conjugate Market include NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc, ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, Navrogen, Inc., and others.
• Promising Antibody Drug Conjugate Pipeline Therapies in the various stages of development include Mirvetuximab Soravtansine, Datopotamab deruxtecan, Ladiratuzumab vedotin, STI-6129, MYTX-011, M1231, NBE-002, Sacituzumab Govitecan, IMGN151, IMGC936, REGN5093-M114, ASN004, TR1801-ADC, STRO-001, OBI-999, YL201, TORL-2-307-ADC, ARX788, and others.

Request a sample and discover the recent advances in Antibody Drug Conjugate Drugs @ Antibody Drug Conjugate Competitive Landscape Report- https://www.delveinsight.com/sample-request/antibody-drug-conjugate-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Antibody Drug Conjugate Pipeline Report provides in-depth commercial assessment of ADC drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the Antibody Drug Conjugate pipeline report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Antibody Drug Conjugate Overview
Antibody-drug conjugates (ADC) are one of the fastest growing anticancer drugs. This approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and therefore toxicity. ADCs are complex molecules that require careful attention to various components.

Find out more about Antibody Drug Conjugate-Analytical Perspective: In-depth Commercial Assessment @ Antibody Drug Conjugate Collaboration Analysis by Companies- https://www.delveinsight.com/sample-request/antibody-drug-conjugate-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Antibody Drug Conjugate Pipeline Therapies and Companies
• Jiangsu Hengrui Medicine Co Ltd.: SHR-A1811
• Seagen Inc.: Ladiratuzumab Vedotin
• ImmunoGen Inc.: IMGN151
• Daiichi Sankyo: DS-6000

Antibody Drug Conjugate Pipeline Analytical Perspective
The Antibody Drug Conjugate pipeline report provides in-depth commercial assessment of Antibody Drug Conjugate drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the Antibody Drug Conjugate pipeline report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Antibody Drug Conjugate Pipeline Report Assessment
• Antibody Drug Conjugate Company Analysis
• Antibody Drug Conjugate Pipeline Therapeutic Assessment
• Antibody Drug Conjugate Pipeline Assessment
• Inactive Antibody Drug Conjugate drugs assessment
• Antibody Drug Conjugate Unmet Needs

Learn more about the emerging Antibody Drug Conjugate Competitive Landscape @ Antibody Drug Conjugate Market Drivers and Barriers, Unmet Needs- https://www.delveinsight.com/sample-request/antibody-drug-conjugate-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Antibody Drug Conjugate Competitive Landscape Report
• Coverage- Global
• Antibody Drug Conjugate Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
• Antibody Drug Conjugate Companies- NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc, ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, Navrogen, Inc., and others.
• Antibody Drug Conjugate Pipeline Therapies- Mirvetuximab Soravtansine, Datopotamab deruxtecan, Ladiratuzumab vedotin, STI-6129, MYTX-011, M1231, NBE-002, Sacituzumab Govitecan, IMGN151, IMGC936, REGN5093-M114, ASN004, TR1801-ADC, STRO-001, OBI-999, YL201, TORL-2-307-ADC, ARX788, and others.

Dive deep into rich insights for new drugs for Antibody Drug Conjugate Product Developmental Activities, Visit @ Antibody Drug Conjugate Research and Development Activities- https://www.delveinsight.com/sample-request/antibody-drug-conjugate-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Antibody Drug Conjugate Executive Summary
3. Antibody Drug Conjugate Overview
4. Antibody Drug Conjugate-Analytical Perspective: In-depth Commercial Assessment
5. Antibody Drug Conjugate Competitive Landscape
6. Antibody Drug Conjugate Therapeutic Assessment
7. Antibody Drug Conjugate: Company and Product Profiles (Marketed Therapies)
8. Pfizer
9. MYLOTARG
10. Antibody Drug Conjugate: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. ADC Therapeutics
13. Zynlonta
14. Drug profiles in the detailed report.....
15. Mid Stage Products (Phase II)
16. Seagen Inc.
17. Ladiratuzumab Vedotin
18. Drug profiles in the detailed report.....
19. Early Stage Products (Phase I)
20. ImmunoGen, Inc.
21. IMGN151
22. Drug profiles in the detailed report.....
23. Preclinical and Discovery Stage Products
24. Company Name
25. Product Name
26. Drug profiles in the detailed report.....
27. Inactive Products
28. Antibody Drug Conjugate - Unmet needs
29. Antibody Drug Conjugate- Market drivers and barriers
30. Appendix

For further information on the Antibody Drug Conjugate Report @ Antibody Drug Conjugate Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/antibody-drug-conjugate-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of the Top Selling Market Research Reports in 2025
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
vulvar cancer market- https://www.delveinsight.com/report-store/vulvar-cancer-pipeline-insight
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
phototherapies for psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
sepsis market- https://www.delveinsight.com/report-store/sepsis-market-insight
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
cart pipeline- https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape
dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
total knee arthroplasty market- https://www.delveinsight.com/report-store/knee-reconstruction-devices-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.